The use of VEGF/VEGFR therapy could promote the extravasation and migration of immune inflammatory cells, thus enhancing the immune inflammatory response after the application of immunotherapy drugs, increasing the drugs’ activity against tumor cells and thereby improving the efficacy of immunotherapy drugs (Manegold et al. 2017). Here, KDR is linked to neoplasm.